Julian Gabor

Julian Gabor

Auto-generated profile, based on publicly available information

Julian Gabor

Institut für Tropenmedizin, Reisemedizin und Humanparasitologie, Universitätsklinikum Tübingen, Innere Medizin IV, Wilhelmstr. 27, 72074, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
Thirumalaisamy P. VelavanThirumalaisamy P. Velavan
Thirumalaisamy P. Velavan
LLLe Thi Kieu Linh
Le Thi Kieu Linh
Andrea KreidenweissAndrea Kreidenweiss
Andrea Kreidenweiss
JGJulian Gabor
Julian Gabor
SKSanjeev Krishna
Sanjeev Krishna
Peter G. KremsnerPeter G. Kremsner
Peter G. Kremsner
Hypoxemia is readily detectable by assessing SpO2 levels, and these are important in optimizing COVID-19 patient management. Hyperlactatemia is a marker of tissue hypoxia, particularly in patients with increased oxygen requirement and microvascular obstruction. We monitored peripheral venous lactate concentrations in hospitalized patients with moderate to severe COVID-19 (n = 18) and in mild ambulatory COVID-19 patients in home quarantine (n = 16). Whole blood lactate decreased significantly during the clinical course and recovery in hospitalized patients (P = 0.008). The blood lactate levels were significantly higher in hospitalized patients than ambulatory patients (day 1: hospitalized versus ambulatory patients P = 0.002; day 28: hospitalized versus ambulatory patients P = < 0.0001). Elevated lactate levels may be helpful in risk stratification, and serial monitoring of lactate may prove useful in the care of hospitalized COVID-19 patients.

19 September 2022 in hautnah dermatologie
Verified
Journal Article
Closed access
ENEva-Maria Neurohr
Eva-Maria Neurohr
JGJulian Gabor
Julian Gabor
CKCarsten Köhler
Carsten Köhler

1 May 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JGJulian J. Gabor
Julian J. Gabor
Andrea KreidenweissAndrea Kreidenweiss
Andrea Kreidenweiss
SWStefan Weber
Stefan Weber
MSMoaaz Salama
Moaaz Salama
MSMihaly Sulyok
Mihaly Sulyok
PKPeter G. Kremsner
Peter G. Kremsner
Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 are at risk of hydroxychloroquine interactions with co-morbidities and co-medications contributing to detrimental, including fatal, adverse treatment effects. A retrospective survey was undertaken of health conditions and co-medications of patients with COVID-19 who were pre-screened for enrolment in a randomized, double-blind, placebo-controlled hydroxychloroquine multi-centre trial. The survey involved 305 patients [median age 71 (interquartile range 59-81) years]. The majority of patients (n = 279, 92%) considered for inclusion in the clinical trial were not eligible, mainly due to safety concerns caused by health conditions or co-medications. The most common were QT-prolonging drugs (n = 188, 62%) and haematologic/haemato-oncologic diseases (n = 39, 13%) which prohibited the administration of hydroxychloroquine. In addition, 165 (54%) patients had health conditions and 167 (55%) patients were on co-medications that did not prohibit the use of hydroxychloroquine but had a risk of adverse interactions with hydroxychloroquine. The most common were diabetes (n = 86, 28%), renal insufficiency (n = 69, 23%) and heart failure (n = 58, 19%). The majority of hospitalized patients with COVID-19 had health conditions or took co-medications precluding safe treatment with hydroxychloroquine. Therefore, hydroxychloroquine should be administered with extreme caution in elderly patients with COVID-19, and only in clinical trials.

2 June 2022 in MMW - Fortschritte der Medizin
Verified
Journal Article
Closed access
ENEva-Maria Neurohr
Eva-Maria Neurohr
JGJulian Gabor
Julian Gabor
CKCarsten Köhler
Carsten Köhler